Cara Therapeutics and Chong Kun Dang Pharmaceutical have signed licensing contract to develop and market CR845, an analgesic drug candidate, in the Republic of Korea. As a part of the agreement, Cara is eligible to gain an up-front ...
Tags: analgesic drug candidate, licensing contract, CR845, Cara Therapeutics